Solid Biosciences Inc. SLDB 深 滬
已收盤 04-02 16:00:00 美东时间
7.49
+0.110
+1.49%
華盛通- 最 高7.8154
- 今 開7.12
- 成交量 80.88万股
- 最 低 7.01
- 昨 收 7.38
- 總市值 7.37亿
- 52周最高 8.72
- 市盈率 靜 --
- 換手率 0.82%
- 52周最低 2.41
- 委 比 51.74%
- 總股本 9839.13万
- 歷史最高 822.60
- 量 比 0.66
- 振 幅 10.91%
- 歷史最低 1.81
- 每 手 1
- 風險率 1.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高240美元，潜在涨幅53%！ARM获多家大行上调目标价；Braze 评级上演 “两极反转”，小摩、巴克莱上调，高盛、花旗下调
今日重点评级关注：HC Wainwright & Co.：维持OCUGEN"买入"评级，目标价从7美元升至10美元；HC Wainwright & Co.：维持Maze Therapeutics"买入"评级，目标价从60美元升至110美元
03-26 11:41
美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
Needham Reiterates Buy on Solid Biosciences, Maintains $19 Price Target
Needham analyst Gil Blum reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $19 price target.
03-20 17:27
Solid Biosciences Files Prospectus Related To Resale Of Up To 1.3M Shares By Selling Stockholder
-SEC Filing
03-20 05:14
Solid Biosciences Q4 EPS $(0.53) Misses $(0.50) Estimate
Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.50) by 5.79 percent. This is a 47 percent increase over losses of $(1.00) per share from
03-20 04:23
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Solid Biosciences reported positive interim data for SGT-003 in Duchenne muscular dystrophy, with the Phase 3 IMPACT DUCHENNE trial expected to begin dosing in April 2026. The company also initiated dosing for SGT-212 in Friedreich’s ataxia and activated clinical sites for SGT-501 targeting CPVT. Solid completed a $240 million private placement, extending its cash runway into H1 2028, and reported financial results for Q4 and full year 2025, incl...
03-19 20:12
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
Solid Biosciences Publishes Updated Corporate Presentation Online
Solid Biosciences Publishes Updated Corporate Presentation Online Solid Biosciences said it posted an updated corporate presentation on its website. The presentation includes an interim update from the Phase 1/2 INSPIRE DUCHENNE trial of SGT-003, reporting that 40 participants had been dosed as of M
03-12 18:03
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
